あなたはここにいる:ホーム > お知らせ
08
14
2015
AstraZeneca’s MedImmune subsidiary will acquire exclusive rights to Inovio Pharmaceuticals’ Phase I/II INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, the companies said today. MedImmune and Inovio will also collaborate to develop up to two more cancer vaccine candidates under a license agreement and collaboration that could generate up to $727.5 million-plus for Inovio.
08
13
2015
The momentum of a cancer’s attack can be used against the cancer, say scientists who practice a form of molecular judo. Instead of directly blocking the action of cancer-causing genes, the scientists use this action against cancer cells, throwing them off balance. Committed to a super-stimulated state, cancer genes can’t help but generate a super-abundance of proteins, which pile up, unfolded, overwhelming the cancer cells’ protein-processing machinery, triggering a stress response, and—finally—bringing the cancer cells down.
08
13
2015
Scientists at the University of Southern California say they have developed a yeast model to study a gene mutation that disrupts the duplication of DNA, causing massive damage to a cell's chromosomes, while somehow allowing the cell to continue dividing.
08
12
2015
Although heart disease still represents the leading cause of death worldwide, genomic studies have increasingly helped scientists zero in on a number of likely causes. For example, mitral valve prolapse (MVP), which affects 2-3% of the population, has not been previously associated with a specific genetic mutation even though it was seen to occur frequently in certain families.
08
12
2015
Scientists at Ohio State University say they have discovered how bacteria use toxins to interrupt the immune response. The researchers say it's important to understand how the toxins work because they are key to enabling bacteria to cause disease.